Pharmacokinetics and Pharmacodynamics of the Nitroimidazole DNDI-0690 in Mouse Models of Cutaneous Leishmaniasis

Authors: Gert-Jan Wijnant, Simon L. Croft, Raúl de la Flor, Mohammad S. Alavijeh, Vanessa Yardley, Stéphanie Braillard, Charles E. Mowbray, Katrien Van Bocxlaer - Antimicrobial Agents and Chemotherapy 2019 cited by 41

The nitroimidazole DNDI-0690 is a clinical drug candidate for visceral leishmaniasis (VL) that also shows potent in vitro and in vivo activity against cutaneous leishmaniasis (CL). To support further development of this compound into a patient-friendly oral or topical formulation for the treatment of CL, we investigated the free drug exposure at the dermal site of infection and subsequent elimination of the causative Leishmania pathogen.